Opportunity Information: Apply for PAR 20 159
This funding opportunity, titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)" (PAR 20-159), is a National Institutes of Health (NIH) discretionary grant program in the health category (CFDA 93.242). Its central purpose is to support early-stage, innovative research that digs into the underlying mechanisms that drive neuropsychiatric symptoms in people living with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). In practical terms, the FOA is aimed at studies that move beyond simply describing symptoms and instead clarify how and why symptoms emerge, worsen, or vary across individuals, with an emphasis on producing mechanistic insights that can ultimately inform better prevention and treatment strategies.
The scientific focus is specifically on mechanisms linked to neuropsychiatric symptoms (NPS) in dementia, which commonly include problems such as agitation, aggression, depression, anxiety, apathy, sleep disruption, psychosis, irritability, and other behavioral or emotional changes that often accompany cognitive decline. The FOA emphasizes that successful applications should strengthen mechanistic understanding across both biobehavioral and neurobiological pathways. That framing signals interest in work that can connect behavior and clinical presentation to measurable biological, physiological, neural circuit, genetic, molecular, or systems-level processes, as well as studies that examine how environmental, caregiving, social, or behavioral factors interact with brain changes to produce NPS. The expected payoff is clearer causal or contributory models of NPS in AD/ADRD rather than purely correlational findings.
A major theme in the announcement is translation potential: by identifying and validating mechanisms, the funded projects are expected to point toward novel therapeutic targets. Even if a given study is not itself a full intervention trial, the goal is that it will generate evidence strong enough to justify future intervention development, including treatments intended to reduce existing neuropsychiatric symptoms or prevent their onset as dementia progresses. The "Clinical Trial Optional" designation means applicants may propose either non-clinical-trial mechanistic studies or clinical trials, depending on what best fits the mechanistic question. This provides flexibility for projects that might include experimental manipulations, proof-of-concept testing, or other designs that meet the NIH definition of a clinical trial, while still keeping the core emphasis on mechanism.
The grant mechanism is an R21, which is typically used by NIH to support exploratory and developmental research projects that are high-risk/high-reward, generate preliminary data, or test novel hypotheses. The opportunity lists an award ceiling of $200,000, aligning with the smaller, pilot-style scope common to R21 projects. While the listing does not specify the number of expected awards, the intent is clearly to seed innovative mechanistic work that can later be expanded into larger projects or intervention programs if findings are compelling.
Eligibility is broad and includes many types of U.S. domestic organizations and, notably, some non-U.S. participation as well. Eligible applicants include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities and Indian housing authorities; nonprofit organizations both with and without 501(c)(3) status (excluding institutions of higher education in those categories); for-profit organizations (other than small businesses); and small businesses. The FOA also explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions; Asian American, Native American, and Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; U.S. territories or possessions; regional organizations; and non-domestic (non-U.S.) entities (foreign organizations). This breadth suggests an interest in attracting diverse research teams and settings, potentially including community-based or underserved populations where NPS burden and care challenges can be substantial.
Key administrative details in the listing include the NIH as the sponsoring agency, the creation date of March 31, 2020, and an original closing date of May 7, 2023. Overall, the opportunity is best understood as a targeted NIH initiative to accelerate discovery of the biological and biobehavioral drivers of neuropsychiatric symptoms in AD/ADRD, with the explicit expectation that clearer mechanisms will open doors to new, more effective therapeutic approaches for patients and caregivers dealing with some of the most disruptive and distressing aspects of dementia.Apply for PAR 20 159
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242.
- This funding opportunity was created on 2020-03-31.
- Applicants must submit their applications by 2023-05-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the title of this funding opportunity?
The funding opportunity is titled "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)" and is identified as PAR 20-159.
Which agency is sponsoring this opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
What kind of grant program is this?
This is an NIH discretionary grant program in the health category, listed under CFDA 93.242.
What is the main purpose of the grant?
The central purpose is to support early-stage, innovative research that investigates the underlying mechanisms that drive neuropsychiatric symptoms (NPS) in people living with Alzheimer's disease (AD) or Alzheimer's disease-related dementias (ADRD). The goal is to move beyond describing symptoms and instead clarify how and why symptoms emerge, worsen, or differ across individuals.
What are neuropsychiatric symptoms (NPS) in the context of dementia?
NPS are behavioral and emotional symptoms that often occur alongside cognitive decline in dementia. The opportunity highlights examples such as agitation, aggression, depression, anxiety, apathy, sleep disruption, psychosis, irritability, and other behavioral or emotional changes.
What types of research does the FOA emphasize?
The FOA emphasizes mechanistic research that strengthens understanding across both biobehavioral and neurobiological pathways. It is aimed at studies that explain drivers and contributors to NPS, rather than studies that only describe symptom patterns.
What does "mechanistic" research mean in this FOA?
In this FOA, "mechanistic" research refers to studies designed to identify and clarify the processes that cause or contribute to NPS in AD/ADRD. The emphasis is on producing clearer causal or contributory models of NPS rather than purely correlational findings.
What kinds of mechanisms are of interest?
The FOA signals interest in mechanisms that can connect behavior and clinical presentation to measurable processes, including biological, physiological, neural circuit, genetic, molecular, or systems-level factors. It also indicates interest in how environmental, caregiving, social, or behavioral factors interact with brain changes to produce NPS.
Does this opportunity support research that includes environmental or caregiving factors?
Yes. The description explicitly notes interest in studies examining how environmental, caregiving, social, or behavioral factors interact with brain changes to produce neuropsychiatric symptoms.
Is the focus limited to describing symptoms like agitation or depression?
No. The FOA is specifically aimed at studies that move beyond symptom description and instead clarify how and why symptoms emerge, worsen, or vary across individuals, with an emphasis on mechanistic insight.
What is the expected impact of funded projects?
The expected payoff is improved mechanistic understanding of NPS in AD/ADRD that can inform better prevention and treatment strategies, including identifying and validating mechanisms that point toward novel therapeutic targets.
Does a project need to be a treatment trial to be competitive?
Not necessarily. The FOA emphasizes translation potential toward future prevention and treatment strategies, but a proposed study does not have to be a full intervention trial as long as it produces mechanistic insights strong enough to justify future intervention development.
What does "Clinical Trial Optional" mean?
"Clinical Trial Optional" means applicants may propose either non-clinical-trial mechanistic studies or clinical trials, depending on what best fits the mechanistic question. This provides flexibility for projects that include experimental manipulations, proof-of-concept testing, or other designs that meet the NIH definition of a clinical trial.
What grant mechanism is used for this opportunity?
The grant mechanism is an R21, which NIH typically uses for exploratory and developmental projects that are high-risk/high-reward, test novel hypotheses, or generate preliminary data.
What is the typical scope of an R21 in this context?
Based on the description, the R21 scope is pilot-style and exploratory, intended to seed innovative mechanistic work that could later be expanded into larger projects or intervention programs if findings are compelling.
What is the award ceiling for this opportunity?
The opportunity lists an award ceiling of $200,000.
How many awards will NIH make?
The listing does not specify the number of expected awards.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. domestic organizations and also allows some non-U.S. participation. Eligible applicants include various government entities, institutions of higher education (public and private), tribal governments and tribal organizations (including those not federally recognized), housing authorities, nonprofits (with and without 501(c)(3) status, excluding institutions of higher education in those categories), for-profit organizations (other than small businesses), and small businesses.
Are minority-serving institutions specifically included as eligible applicants?
Yes. The FOA explicitly highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions; AANAPISIs; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); and Tribally Controlled Colleges and Universities (TCCUs).
Can faith-based or community-based organizations apply?
Yes. Faith-based or community-based organizations are explicitly included in the list of highlighted eligible applicant types.
Are U.S. territories or regional organizations eligible?
Yes. The eligibility list explicitly includes U.S. territories or possessions and regional organizations.
Are foreign (non-U.S.) organizations eligible to apply?
Yes. The eligibility description explicitly includes non-domestic (non-U.S.) entities (foreign organizations).
Does the FOA encourage work in diverse settings or populations?
While the FOA does not state a specific population requirement in the provided information, the breadth of eligible organization types (including community-based organizations and a wide range of institutions) suggests interest in attracting diverse research teams and settings, potentially including underserved populations where NPS burden and care challenges can be substantial.
When was this opportunity created?
The listing provides a creation date of March 31, 2020.
What was the original closing date?
The original closing date listed is May 7, 2023.
What diseases or conditions are the focus of the research?
The research focus is Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD), specifically targeting neuropsychiatric symptoms within these conditions.
What kind of outcomes or deliverables are implied by the FOA?
The FOA implies deliverables centered on mechanistic insight: clearer causal or contributory models of NPS in AD/ADRD and evidence that can point toward and justify future development of interventions or treatments to prevent or reduce NPS.
Browse more opportunities from the same category: Health
Next opportunity: Annual Program Statement for Public Affairs Dhaka
Previous opportunity: Development of Highly Innovative Tools and Technology for Analysis of Single Cells (SBIR) (R43/R44 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 20 159
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 20 159) also looked into and applied for these:
| Funding Opportunity |
|---|
| Furthering Health System Reforms in Ukraine Apply for RFI 121 20 000001 Funding Number: RFI 121 20 000001 Agency: Ukraine USAID-Kiev Category: Health Funding Amount: Case Dependent |
| Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD) Exploratory/Developmental Research Projects (UH2 Clinical Trial Optional) Apply for RFA AA 20 008 Funding Number: RFA AA 20 008 Agency: National Institutes of Health Category: Health Funding Amount: $175,000 |
| NIMH Biobehavioral Research Awards for Innovative New Scientists (NIMH BRAINS) (R01 Clinical Trial Optional) Apply for RFA MH 20 525 Funding Number: RFA MH 20 525 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Competitive Revision Supplements to Existing AHRQ Health Service Research (HSR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) Apply for PA 20 070 Funding Number: PA 20 070 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Novel, High-Impact Studies Evaluating Health System and Healthcare Professional Responsiveness to COVID-19 (R01) Apply for RFA HS 20 003 Funding Number: RFA HS 20 003 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Clinical Trials in Organ Transplantation in Children and Adults (CTOT-CA) (U01 Clinical Trial Optional) Apply for RFA AI 20 029 Funding Number: RFA AI 20 029 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementation Research to Improve Case Finding, Cascade Screening, and Treatment for Familial Hypercholesterolemia (FH) (R61/R33 Clinical Trial Required) Apply for RFA HL 22 006 Funding Number: RFA HL 22 006 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Pilot Projects Investigating Understudied G Protein-Coupled Receptors, Ion Channels, and Protein Kinases (R03 Clinical Trial Not Allowed) Apply for RFA RM 20 019 Funding Number: RFA RM 20 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Noninvasive mTBI Tool RFI Apply for HU000120R0047 Funding Number: HU000120R0047 Agency: Uniformed Services Univ. of the Health Sciences Category: Health Funding Amount: Case Dependent |
| IDeA Program Infrastructure for Clinical and Translational Research (IDeA-CTR)(U54 - Clinical Trial Optional) Apply for PAR 20 175 Funding Number: PAR 20 175 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Mucosal Immunology Studies Team (MIST) (U01 Clinical Trial Not Allowed). Apply for RFA AI 20 027 Funding Number: RFA AI 20 027 Agency: National Institutes of Health Category: Health Funding Amount: $350,000 |
| Competitive Revision Supplements to Existing AHRQ Patient Centered Outcomes Research (PCOR) Grants and Cooperative Agreements to Evaluate Health System and Healthcare Professional Responsiveness to COVID-19 (Supplement - Clinical Trial Optional) Apply for PA 20 072 Funding Number: PA 20 072 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: Case Dependent |
| Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) Apply for PAR 20 178 Funding Number: PAR 20 178 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) Apply for PAR 20 177 Funding Number: PAR 20 177 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Network Management Core (NEMO) for the Pulmonary Trials Cooperative (PTC) Disease Modifying Therapies for Chronic Lung Diseases (U24 Clinical Trial Required - Infrastructure) Apply for RFA HL 21 012 Funding Number: RFA HL 21 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Disease Modifying Therapies for Chronic Lung Disease (R61/R33 Clinical Trial Required) Apply for RFA HL 21 013 Funding Number: RFA HL 21 013 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Frontier Health Markets (FHM) Apply for RFI 20 GH FHM 01 Funding Number: RFI 20 GH FHM 01 Agency: Agency for International Development Category: Health Funding Amount: $250,000,000 |
| Research Program Award (R35 Clinical Trial Optional) Apply for RFA NS 20 030 Funding Number: RFA NS 20 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Clinical Trial Required) Apply for PAR 20 209 Funding Number: PAR 20 209 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Physician-Scientist Pathway to Independence Award (K99/R00 Independent Clinical Trial Not Allowed) Apply for PAR 20 210 Funding Number: PAR 20 210 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 20 159", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.